Skip to content

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-189.5%-8,509pp
AbbVie logo
AbbVieABBV
89%+32.7pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-70%+8.4pp
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-85.7%+1.7pp

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

Based on trailing twelve months.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s return on equity?
SELLAS Life Sciences Group, Inc. (SLS) reported return on equity of -43.6% in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s return on equity changed year-over-year?
SELLAS Life Sciences Group, Inc.'s return on equity increased by 69.9% year-over-year, from -144.9% to -43.6%.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s return on equity?
Over 3 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s return on equity has grown at a -12.1% compound annual growth rate (CAGR), from -98.4% to -66.9%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.